Patents for A61P 35 - Antineoplastic agents (221,099)
03/2006
03/20/2006WO2006102191A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
03/20/2006CA2600175A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
03/17/2006CA2477867A1 Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same
03/16/2006WO2006029275A2 Methods of using death receptor ligands and cd20 antibodies
03/16/2006WO2006029224A2 Methods of using death receptor ligands and cd20 antibodies
03/16/2006WO2006029146A2 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
03/16/2006WO2006028958A2 Pyridyl inhibitors of hedgehog signalling
03/16/2006WO2006028226A1 Novel imidazolidine derivative and use thereof
03/16/2006WO2006028197A1 Anti-a33 antibody
03/16/2006WO2006028160A1 S-oligonucleotide conjugate and antisense agent
03/16/2006WO2006028122A1 Agent for preventing and ameliorating obesity
03/16/2006WO2006028110A1 Process for producing water-soluble hyaluronic acid modification
03/16/2006WO2006028038A1 Sulfonamide derivative selectively inhibiting mmp-13
03/16/2006WO2006027365A1 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity
03/16/2006WO2006012502A3 Formulation of insoluble small molecule therapeutics in lipid-based carriers
03/16/2006WO2005106488A3 Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
03/16/2006WO2005030260A8 Bispecific oligonucleotide for the treatment of cns malignancies
03/16/2006US20060058553 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
03/16/2006US20060058541 Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
03/16/2006US20060058523 Quinazoline compounds
03/16/2006US20060058522 2-[(aminocarbonyl)amino]-5-(4-{[2,2,2-trifluoroethyl)amino]methyl}phenyl)thiophene-3-carboxamide; I kappa B kinase-1(IKK-1) inhibitors; asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, chronic obstructive pulmonary disease, bone resorptive disease, osteoarthritis
03/16/2006US20060058520 Detecting activity of a Silent information regulator 2 by combining the composition with adenosine 5'-diphosphate and an acetylated Sir2 peptide substrate to deacetylate the peptide, and identifying 2'/3'-O-acetyl-ADP-ribose in the mixture to determine the presence of Sir2 activity
03/16/2006US20060058516 Novel serine-threonine kinase
03/16/2006US20060058512 Process for producing humanized chimera antibody
03/16/2006US20060058505 Nucleic acid and polypeptide linked to breast cancer and uses therefor
03/16/2006US20060058398 Medicinal compositions containing vitamin k's as nerve growth factor potentiator and utilization thereof
03/16/2006US20060058395 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
03/16/2006US20060058389 Novel compounds that inhibit factor xa activity
03/16/2006US20060058381 Pharmaceutical formulation comprising (r)-bicalitamide
03/16/2006US20060058379 Connexin 26 inhibitor and cancer metastasis inhibitors
03/16/2006US20060058371 Inhibiting pathological activation of the transcription factor NF- kappa B (nuclear factor- kappa B); amino-benzothiophene compounds, therapy of inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and chronic obstructive pulmonary disease
03/16/2006US20060058362 7-Amido-isoindolyl compounds and methods of their use
03/16/2006US20060058349 Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
03/16/2006US20060058325 Therapeutic quniazoline derivatives
03/16/2006US20060058324 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives
03/16/2006US20060058318 Prodrugs of an ERK protein kinase inhibitor
03/16/2006US20060058313 Treatment of mesothelioma
03/16/2006US20060058307 Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
03/16/2006US20060058306 Solubilized topoisomerase poison agents
03/16/2006US20060058305 Antiproliferative agents such as 3-(3-trifluoromethylphenyl)cinnolin-5-ol
03/16/2006US20060058304 Azaindole kinase inhibitors
03/16/2006US20060058302 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases; example compound: 2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(2-ethyl-hexyl)-benzamide
03/16/2006US20060058298 Inhibitors of histone deacetylase
03/16/2006US20060058295 Novel compounds as pharmaceutical agents
03/16/2006US20060058288 Severe sepsis preventive therapeutic agent
03/16/2006US20060058282 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
03/16/2006US20060058270 Ruthenium anticancer complexes
03/16/2006US20060058260 Combination therapy with gemcitabine and zd6126
03/16/2006US20060058258 Gene transcription and ionizing radiation: methods and compositions
03/16/2006US20060058253 Methods to reprogram splice site selection in pre-messenger rnas
03/16/2006US20060058252 Methods and materials for treating human papillomavirus infections
03/16/2006US20060058251 Use of immunostimulatory nucleic acids containing unmethylated CpG dinucleotide sequences to treat viral infections; use with viral antigen in vaccine or without a viral antigen
03/16/2006US20060058227 Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis
03/16/2006US20060058226 Gd3-mimetic peptides
03/16/2006US20060057714 Vector
03/16/2006US20060057663 Novel g protein-coupled receptor protein and dna thereof
03/16/2006US20060057649 Screening method and anti-tumor drug candidate obtained therefrom
03/16/2006US20060057648 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
03/16/2006US20060057628 Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof
03/16/2006US20060057574 Tissue specific expression
03/16/2006US20060057237 Extract with anti-tumor and anti-poisonous activity
03/16/2006US20060057219 Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection
03/16/2006US20060057162 Induction of cytotoxic T-lymphocyte responses
03/16/2006US20060057147 Antibody recognizing antibody
03/16/2006US20060057146 Selective targeting of tumor vasculature using antibody molecules
03/16/2006US20060057139 Process for producing humanized chimera antibody
03/16/2006US20060057136 Immunotherapy of B-Cell malignancies using anti-CD22 antibodies
03/16/2006US20060057130 An isolated RNA-pulsed antigen presenting cell comprising tumor specific RNA; stimulation of cytotoxic T-lymphocyte proliferation ex vivo or in vivo for adoptive immunotherapy; anticarcinogenic agents; antitumor agents; bactericides; viricides
03/16/2006US20060057117 Vascular endothelial growth factor 2
03/16/2006US20060057113 Novel adenoviruses, nucleic acids coding therefor, and use thereof
03/16/2006US20060057099 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
03/16/2006DE10394214T5 Methyl-B-Orcinolcarboxylat aus Flechten (Everniastrum cirrhatum) zur Verwendung für die Behandlung von Pilzinfektionen und Krebs Methyl-B-Orcinolcarboxylat from lichens (Everniastrum cirrhatum) for use in the treatment of fungal infections and cancer
03/16/2006DE102004040014A1 New aureonitrile compounds useful as cytostatic agents, fungicides and antibiotics
03/16/2006CA2591321A1 Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
03/16/2006CA2583375A1 Regulation of oncogenes by micrornas
03/16/2006CA2579886A1 Novel imidazolidine derivative and use thereof
03/16/2006CA2579660A1 Beta-glucuronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators
03/16/2006CA2579558A1 Cancer-testis antigens
03/16/2006CA2579533A1 Drug delivery from embolic agents
03/16/2006CA2579302A1 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity
03/16/2006CA2579102A1 Compositions and methods for the diagnosis and treatment of tumor
03/16/2006CA2578958A1 Acetylated starch or starch succinate for treatment of obesity or diabetes
03/16/2006CA2578164A1 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
03/16/2006CA2578052A1 Methods of activating nkt cells
03/16/2006CA2577828A1 Methods of using death receptor ligands and cd20 antibodies
03/16/2006CA2577823A1 Methods of using death receptor ligands and cd20 antibodies
03/16/2006CA2575997A1 Carrier conjugates of gnrh-peptides
03/16/2006CA2565235A1 [3.2.0] heterocyclic compounds and methods of using the same
03/15/2006EP1634949A1 Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
03/15/2006EP1634892A2 Composition and methods for the diagnosis of tumours
03/15/2006EP1634881A1 Harmine derivatives, intermediates used in their preparation, preparation processes and use thereof
03/15/2006EP1634874A1 Imidazolidine derivative
03/15/2006EP1634601A2 Dietary supplement comprising soyabean, mushroom and mung bean
03/15/2006EP1634600A1 Antiallergic composition
03/15/2006EP1634594A1 Use of 3-substituted oxindole derivatives as KCNQ potassium channel modulators
03/15/2006EP1634498A2 Exo-S-mecamylamine formulation
03/15/2006EP1634081A2 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
03/15/2006EP1633883A1 Method for assaying lkb1 phosphorylation activity
03/15/2006EP1633784A2 Ovr110 antibody compositions and methods of use
03/15/2006EP1633773A2 D-amino acid peptides